Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2018 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The transcript: management talks about various projects, but does it convey that the size of deals/contracts/projects is escalating? For example, they mention the Sooner scrubber project, Mustang Energy Centers, Windspeed II, Covington solar, etc. But they don't compare sizes over time. They mention capacity needs: 168 MW by 2019, 305 MW by 2020. That's a need, not necessarily larger deals. They mention RFP for capacity. They mention data center sector expansion, electrification of compressors. But no explicit statement that each new instance is bigger than before. They talk about customer growth, sales growth, but that's volume. They mention "we added over 6,000 new customers" - that's volume. No mention of average size increasing. They mention "we have a large backlog of projects" but not that they are individually larger. They mention "we will deploy capital" but not that deals are bigger. The question asks specifically about successive engagements of the same kind coming in at progressively larger size. There is no such statement. Management does not convey that. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.